Foster

DRUG3 trials

Sponsors

Chiesi Farmaceutici S.p.A., Far Eastern Memorial Hospital

Conditions

AsthmaAsthmatic Patients

Phase 3

A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma

CompletedNCT00862394

Chiesi Farmaceutici S.p.A.Asthma

Start: 2009-02-28End: 2010-01-31Updated: 2018-04-13

Phase 4

FACTO Study (Foster® As Complete Treatment Option)

CompletedNCT00901368

Chiesi Farmaceutici S.p.A.Asthmatic Patients

Start: 2009-05-31End: 2010-12-31Updated: 2017-03-30

Comparison Efficacy in Patients With Asthma Using Foster MDI and Relvar Medications

Far Eastern Memorial HospitalAsthma

Start: 2020-01-01End: 2022-06-30Target: 200Updated: 2019-12-04